Walmart, Walgreens Join MediLedger to Fight Counterfeit Drugs

The retail behemoths have joined the blockchain pharma supply chain project aimed at tackling the counterfeit drug market.

Pharmaceutical Drugs / Image: Ledger Insights
Pharmaceutical Drugs / Image: Ledger Insights

A recent Ledger Insights article discussed MediLedger’s new blockchain project for the FDA Pilot Program. The goal of the project is to establish a functional system for traceability in the U.S. pharmaceutical supply chain that complies with the Drug Supply Chain Security Act regulations that will come into effect in 2023. Among the members are major pharma companies including Pfizer, Genentech, Amgen, Eli Lilly and Gilead.

MediLedger is an open network focused on digital solutions in healthcare with several projects in work. In addition to the blockchain project, MediLedger is also launching a pharma returns traceability solution and exploring a contracting solution.

More in Pharmaceutical